Atrium Therapeutics Inc.
RNA | NASDAQ
$8.27
+$0.01 (+0.12%)
At close: Oct 30, 2026, 4:00 PM ET
$8.33
+$0.06 (+0.73%)
Pre-market:
Nov 2, 2026, 8:40 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Revenue | 3M | 19.64M | 859K | n/a |
Cost of Revenue | 343K | 151K | n/a | n/a |
Gross Profit | 2.66M | 19.48M | 859K | n/a |
Operating Income | -22.62M | -17.28M | -48.04M | -8.46M |
Interest Income | 2.1M | n/a | n/a | n/a |
Pretax Income | -20.19M | -16.63M | -48.04M | -8.46M |
Net Income | -20.19M | -16.63M | -48.07M | -8.29M |
Selling & General & Admin | 9.94M | 20.11M | 30.4M | n/a |
Research & Development | 15.34M | 16.66M | 18.5M | n/a |
Other Expenses | n/a | n/a | n/a | 8.46M |
Operating Expenses | 25.28M | 36.76M | 48.89M | 8.46M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | -5.77M |
Cost & Expenses | 25.62M | 36.92M | 48.89M | 8.46M |
Income Tax Expense | n/a | n/a | 34K | -176K |
Shares Outstanding (Basic) | 17.11M | 17.11M | 17.11M | n/a |
Shares Outstanding (Diluted) | 17.11M | 17.11M | 17.11M | n/a |
EPS (Basic) | -1.18 | -0.97 | -1.70 | n/a |
EPS (Diluted) | -1.18 | -0.97 | -1.70 | n/a |
EBITDA | -22.28M | -16.48M | -47.91M | -8.39M |
EBIT | -22.62M | -16.63M | -48.04M | -8.46M |
Depreciation & Amortization | 343K | 151K | 122K | 69K |
Add to Watchlist
Select watchlists to add or remove RNA